Drugs / Cetuximab-IRDye800CW
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05376202 | Mar 2022 → May 2023 | squamous cell carcinoma of penis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03134846 | Dec 2017 → Dec 2021 | head and neck squamous cell carcinoma | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 1/2 | NCT02855086 | Oct → Nov 2016 | brain neoplasm, malignant glioma | Eben Rosenthal | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cetuximab-IRDye800CW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05376202 ↗ |
| Modality | Diagnostic / imaging agent | “Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.” NCT02855086 ↗ |
| Route | Intravenous | “Administered intravenously (IV)” NCT02855086 ↗ |
| Target | EGFR | “against Epidermal Growth Factor Receptor, i.e. cetuximab-IRDye800CW, in patients with HNSCC” NCT03134846 ↗ |